$AVAI

AVAI BIO, INC.

Avai Bio is a technology company that acquires, creates and develops technologies using artificial intelligence, and provides information technology consulting services. Its capabilities include full-stack software development, database management, data integration, project management and cloud services. Its Avant-AI system is a text-generation, deep-learning model that uses unsupervised learning and supervised techniques to process and analyze data. Avai Bio also owns Thy News, a news application that lets users choose and customize feeds from 149,000 processed sources as of December 31, 2025, with additional paid features available by subscription. Avai Bio makes money through information technology consulting services and paid subscriptions to additional Thy News app features. Its corporate address is in Las Vegas, Nevada.

0
1
0

No SEC Form 4 filings for $AVAI in the last 30 days.

See all $AVAI insider activity →
Low

Avai Bio 3Q 2026: Revenue $0, EPS ($0.00) — 10-Q Summary

Avai Bio reported no revenue for 3Q 2026, with a net loss of $253,240, a 44% improvement from the prior year. Operating expenses decreased 36% and other expenses fell to zero. The company acquired the Lifestyle Wellness Assessment API for $58,600. Operating cash use declined $122,313 year over year to $489,577 in the six months ended September 30, 2026.

Biotech Stocks Gain Ground: PDS Biotech, Clene, Indaptus Lead Movers

PDS Biotech (PDSB) announced a $22.55M PIPE financing for late-stage cancer drug development, shares up 50.64%. Avaí Bio (AVAI) completed cell bank testing, shares up 14.29%. Clene (CLNN) priced a $4M offering, shares up 25.25%. NurExone (NRX.V) partnered with NanoPass, shares up 8.06%. Cardiff Oncology (CRDF) settled a licensing dispute, shares up 4.58%. Indaptus (INDP) shares surged 16.88% without specific news.

Avaí Bio Completes Cell Bank Testing, Advances?-Klotho Anti-Aging Therapy

Avaí Bio (AVAI) completed viral and contaminant testing for its GMP Master Cell Bank, confirming it is free of over 30 viruses and other agents. The company, along with Austrianova, is developing a-Klotho-producing cell therapies through their joint venture, Klothonova. The milestone supports further development of the anti-aging therapy. AVAI stock is currently at $0.14, up 21.74%.

AVAI sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning AVAI (AVAI BIO, INC.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.

Recent AVAI coverage spans technology, earnings and market movers.

What's driving AVAI

AlphAI scores every news story that mentions AVAI with an AI model for sentiment and relevance, and aggregates insider trades from AVAI BIO, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $AVAI

Score

Avai Bio 3Q 2026: Revenue $0, EPS ($0.00) — 10-Q Summary

Avai Bio reported no revenue for 3Q 2026, with a net loss of $253,240, a 44% improvement from the prior year. Operating expenses decreased 36% and other expenses fell to zero. The company acquired the Lifestyle Wellness Assessment API for $58,600. Operating cash use declined $122,313 year over year to $489,577 in the six months ended September 30, 2026.

Biotech Stocks Gain Ground: PDS Biotech, Clene, Indaptus Lead Movers

PDS Biotech (PDSB) announced a $22.55M PIPE financing for late-stage cancer drug development, shares up 50.64%. Avaí Bio (AVAI) completed cell bank testing, shares up 14.29%. Clene (CLNN) priced a $4M offering, shares up 25.25%. NurExone (NRX.V) partnered with NanoPass, shares up 8.06%. Cardiff Oncology (CRDF) settled a licensing dispute, shares up 4.58%. Indaptus (INDP) shares surged 16.88% without specific news.

$AVAIMedAI 8/10

Avaí Bio Completes Cell Bank Testing, Advances?-Klotho Anti-Aging Therapy

Avaí Bio (AVAI) completed viral and contaminant testing for its GMP Master Cell Bank, confirming it is free of over 30 viruses and other agents. The company, along with Austrianova, is developing a-Klotho-producing cell therapies through their joint venture, Klothonova. The milestone supports further development of the anti-aging therapy. AVAI stock is currently at $0.14, up 21.74%.

$AVAIMedAI 8/10

Replacing Insulin Cells Works. Keeping The Cells Alive Is the Trick

AVAI Bio, Vertex, and Sana are developing treatments for Type 1 diabetes by replacing insulin-producing beta cells. Vertex's trial showed 10/12 patients stopped using insulin, but all require immunosuppression. Sana's gene-edited cells evaded immune detection. AVAI Bio's joint venture, Insulinova, is testing encapsulated beta cells with Ospedale San Raffaele. No trials or timelines have been announced.

Related tickers